Zhejiang University
Clinical trials sponsored by Zhejiang University, explained in plain language.
-
Arterial chemo combo shows promise in stomach cancer trial
Disease control Recruiting nowThis phase 3 trial tests whether giving chemotherapy directly into the artery (instead of through a vein) along with immunotherapy can better shrink locally advanced stomach cancer before surgery. About 190 participants will receive either the standard chemo regimen or the arteri…
Phase: PHASE3 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted combo trial launches
Disease control Recruiting nowThis phase 2 trial is testing a new drug combination for people with advanced pancreatic cancer that has a specific mutation called KRAS G12D. The treatment combines HRS-4642 (a drug that targets the mutated protein), nimotuzumab (an antibody that blocks a growth signal), and sta…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental CAR-T therapy takes on stubborn cancers
Disease control Recruiting nowThis early-phase trial tests a new cell therapy called UCLH80-1 in 36 people with advanced solid tumors (colorectal, gastric, pancreatic, and bile duct cancers) that have not responded to standard treatments. The therapy uses specially engineered immune cells to target a protein …
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Chemo-Free combo shows promise for Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 2 trial tests two drugs, fulzerasib and cetuximab N01, given before surgery to people with a specific genetic subtype (KRAS G12C mutation) of locally advanced colorectal cancer. The goal is to shrink tumors and improve surgical outcomes without using chemotherapy. Fort…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immune cell therapy shows promise for aggressive blood cancer
Disease control Recruiting nowThis study tests a treatment called CD19 CAR-T therapy for people newly diagnosed with a fast-growing type of blood cancer called high-risk large B-cell lymphoma. The therapy uses a patient's own immune cells, modified to better attack cancer cells. The main goal is to see how ma…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called Meta10-19 for people with moderate to severe systemic lupus erythematosus (SLE). The therapy uses a patient's own immune cells, modified to better target and destroy faulty B cells that drive the disease. The main goals are to f…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if …
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThis early-phase study tests SYNCAR-100, a type of cell therapy (CAR-T), in 16 adults with CD19-positive B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. Participants receive four weekly injections, then are followed for safety and tu…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for pancreatic cancer: targeted combo trial opens
Disease control Recruiting nowThis study tests a new combination of drugs (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if the treatment can shrink the tumor enough for surgery and …
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New Colon-Sparing surgery could improve cancer outcomes
Disease control Recruiting nowThis study compares a newer, less invasive surgery (LISH) that saves part of the colon to the standard surgery (TRH) for people with colon cancer in specific areas. The goal is to see if the newer surgery leads to better long-term survival without the cancer coming back. About 56…
Phase: NA • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control Recruiting nowThis early study tests a new treatment called CG-102-12C for people with advanced liver cancer that has not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will e…
Phase: NA • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Armored immune cells take on liver cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to standard therapies. C-CAR031 uses a patient's own immune cells, modified to better target and attack cancer cells. The trial will enroll 72 participants to…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on advanced liver cancer in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CNCT19 CAR-T cells for people with advanced liver cancer that cannot be removed by surgery or has come back after other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The main go…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Engineered immune cells take aim at tough leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment called IL-5 CAR-T cell therapy for people with a rare and hard-to-treat blood cancer called eosinophilic leukemia. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goals are to check s…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on philadelphia Chromosome-Positive leukemia
Disease control Recruiting nowThis study tests whether specially engineered immune cells (CAR-T cells) can treat adults with a specific, aggressive form of acute lymphoblastic leukemia that has a genetic marker called the Philadelphia chromosome. Fifty newly diagnosed patients will receive an infusion of thes…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope: Chemo-Free cocktail targets advanced colorectal cancer
Disease control Recruiting nowThis study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive these d…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New gene therapy injection shows promise for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for pancreatic cancer: targeted drug combo enters Mid-Stage trial
Disease control Recruiting nowThis phase II study tests a new drug called IBI343, which targets a protein on cancer cells, combined with standard chemotherapy (gemcitabine and albumin-bound paclitaxel) in 64 people with advanced pancreatic cancer. The trial has two parts: a safety lead-in and a randomized ext…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a simple blood test replace colonoscopy for cancer screening?
Diagnosis Recruiting nowThis study compares three ways to screen for colorectal cancer in average-risk people aged 45-74: colonoscopy, a stool test (FIT), and a stool test plus a blood test. Over 60,000 participants will be randomly assigned to one of the three methods. The goal is to see if the simpler…
Phase: NA • Sponsor: Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Could a simple suppository soothe Post-Surgery bladder pain?
Symptom relief Recruiting nowThis study tests whether a rectal indomethacin suppository given right after surgery can prevent or reduce bladder discomfort caused by a urinary catheter in men undergoing laparoscopic radical prostatectomy. About 130 participants will be randomly assigned to receive either the …
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New oxygen method may prevent dangerous drops during routine scopes for sleep apnea patients
Symptom relief Recruiting nowThis study tests whether a high-flow nasal cannula (a device that delivers warm, moist oxygen) can prevent low oxygen levels during sedated gastrointestinal endoscopy in people at high risk for obstructive sleep apnea. About 600 adults with a STOP-Bang score of 5 or higher will b…
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Acupuncture meets medicine: new combo targets Post-Surgery nausea
Symptom relief Recruiting nowThis study tests whether adding a gentle electrical acupoint stimulation (TEAS) to a standard three-drug anti-nausea regimen can further reduce vomiting after laparoscopic surgery. Researchers will compare active TEAS to a sham (fake) version in 780 women at high risk for postope…
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New combo device aims to keep obese patients breathing safely during gut exams
Symptom relief Recruiting nowThis study tests whether a new device that combines a bite block, oxygen tube, and airway support can prevent dangerously low oxygen levels in severely obese patients during sedated endoscopy. About 410 adults with a BMI of 35 or higher will be randomly assigned to receive either…
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New oxygen device may make endoscopy safer for the sickest patients
Symptom relief Recruiting nowThis study tests whether a high-flow nasal cannula (HFNC) can prevent dangerous drops in oxygen levels during sedated gastrointestinal endoscopy in critically ill patients. Researchers will compare HFNC with standard nasal oxygen in 450 adults with serious health conditions. The …
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New device aims to keep oxygen levels up during endoscopy in obese patients
Symptom relief Recruiting nowThis study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen delivery, breathing monitoring, and a bite block to prevent low oxygen levels. Researchers will compare it…
Phase: NA • Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 26, 2026 15:27 UTC
-
New tool could prevent dangerous stomach complications during sedated procedures
Knowledge-focused Recruiting nowThis study aims to develop a simple tool to predict whether a person's stomach will still have food or liquid in it before a sedated endoscopy. Having a full stomach during sedation raises the risk of serious complications like choking. Researchers will study 5,000 adults to iden…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Thousands of surgery patients studied to uncover hidden voice box injuries
Knowledge-focused Recruiting nowThis study looks back at 1,200 people who had a breathing tube placed during surgery to find out how often voice box injury happens and what makes it more likely. Researchers will check medical records and call patients to see if they had hoarseness or other throat problems after…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC